VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPROMISED PATIENTS

伐昔洛韦是安全和有效的治疗局限性带状疱疹的免疫功能低下的患者18岁及以上。 这是一项随机、双盲、对照试验，比较两种剂量的盐酸伐昔洛韦口服治疗18岁及以上免疫功能低下患者的单纯带状疱疹的疗效和安全性。 为了使两个治疗组各有25例患者完成治疗和随访，将66例患者平均随机分配至这两个治疗组。 研究药物首次给药（第1天）必须在带状疱疹发作后72小时内进行。 患者将接受1000 mg或2000 mg伐昔洛韦，每日三次，持续7天。这些药物将口服。 患者参与研究的时间总共为24周。 将在第1、3、6、8、10、14、21和28天观察和评估患者的带状疱疹相关疼痛和/或异常感觉和带状疱疹并发症，然后每4周一次，直至第24周（包括第24周）。 在研究期间，将定期收集对资源使用和生活质量问题的回答。 将通过常规血液学和生化评估以及不良事件报告来监测安全性。

Valacyclovir is safe and effective for treatment of localized herpes zoster in immunocompromised patients 18 years of age and older. This is a randomized, double-blind, controlled trial comparing the efficacy and safety of two doses of oral valacyclovir HCl for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. In order that 25 patients complete therapy and follow-up in each of the two treatment groups, 66 patients will be equally randomized to each of these two treatment groups. Administration of the first dose(day 1) of study drug must occur within 72 hours of zoster rash onset. Patients will receive 1000 mg or 2000 mg valacyclovir three times daily for 7 days. These drugs will be taken orally. Patients' participation will be for a total of 24 weeks. Patients will be seen and assessed for zoster-associated pain and/or abnormal sensations and zoster complications on days 1,3,6,8,10,14,21, and 28 and then every 4 weeks up to and including week 24. Responses to resource use and quality of life questions will be collected at intervals during the study. Safety will be monitored by means of routine hematological and biochemical assessments and reporting of adverse experiences.